Tags

Type your tag names separated by a space and hit enter

[HLA- haploidentical donor hematopoietic transplantation for severe aplastic anemia achieved comparable outcomes with HLA- unrelated donor transplantation].
Zhonghua Xue Ye Xue Za Zhi. 2016 Jan; 37(1):35-8.ZX

Abstract

OBJECTIVE

To evaluate the efficacy of HLA- haploidentical donor hematopoietic transplantation (Haplo- HSCT)for severe aplastic anemia (SAA)by compared with the same period of unrelated donor transplantation (UD- HSCT).

METHODS

Of a cohort of 50 SAA patients between September 2012 and July 2014, 26 patients underwent UD- HSCT and 24 patients Haplo- HSCT.

RESULTS

OS rate was 91.3% with a median follow-up of 9 (2-26)months. According to transplant type, there was no significant difference between UD- and Haplo-HSCT (96.1%vs 86.0%,P=0.30). 3 of 50 (6%)patients had primary engraft failure. Haplo- HSCT developed higher significantly incidence of Ⅱ- Ⅳ aGVHD (37.5%vs 3.83%,P=0.003)and cGVHD (37.5%vs 15.3%,P=0.030)than UD-HSCT. Haplo-HSCT also had significantly higher incidences of CMV viremia (78.2%vs 46.1%,P=0.005)and EBV viremia (43.1%vs 16.0%,P=0.040), respectively than UD-HSCT. But the incidences of hemorrhagic cystitis were similar between two transplant types (39.1%vs 23.0%,P=0.120).

CONCLUSION

This study showed favorable outcome of Haplo-HSCT for SAA, which was comparable with UD-HSCT.

Authors+Show Affiliations

Ludaopei Hematology & Oncology Center, Yanda International Hospital, Hebei Langfang 065200, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

chi

PubMed ID

26876251

Citation

Lu, Yue, et al. "[HLA- Haploidentical Donor Hematopoietic Transplantation for Severe Aplastic Anemia Achieved Comparable Outcomes With HLA- Unrelated Donor Transplantation]." Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, vol. 37, no. 1, 2016, pp. 35-8.
Lu Y, Wu T, Cao X, et al. [HLA- haploidentical donor hematopoietic transplantation for severe aplastic anemia achieved comparable outcomes with HLA- unrelated donor transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2016;37(1):35-8.
Lu, Y., Wu, T., Cao, X., Zhao, Y., Liu, D., Sun, R., Xiong, M., Wei, Z., Zhang, J., Zhou, J., & Lu, D. (2016). [HLA- haploidentical donor hematopoietic transplantation for severe aplastic anemia achieved comparable outcomes with HLA- unrelated donor transplantation]. Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, 37(1), 35-8. https://doi.org/10.3760/cma.j.issn.0253-2727.2016.01.007
Lu Y, et al. [HLA- Haploidentical Donor Hematopoietic Transplantation for Severe Aplastic Anemia Achieved Comparable Outcomes With HLA- Unrelated Donor Transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2016;37(1):35-8. PubMed PMID: 26876251.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [HLA- haploidentical donor hematopoietic transplantation for severe aplastic anemia achieved comparable outcomes with HLA- unrelated donor transplantation]. AU - Lu,Yue, AU - Wu,Tong, AU - Cao,Xingyu, AU - Zhao,Yanli, AU - Liu,Deyan, AU - Sun,Ruijuan, AU - Xiong,Min, AU - Wei,Zhijie, AU - Zhang,Jianping, AU - Zhou,Jiarui, AU - Lu,Daopei, PY - 2016/2/16/entrez PY - 2016/2/16/pubmed PY - 2016/7/7/medline SP - 35 EP - 8 JF - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi JO - Zhonghua Xue Ye Xue Za Zhi VL - 37 IS - 1 N2 - OBJECTIVE: To evaluate the efficacy of HLA- haploidentical donor hematopoietic transplantation (Haplo- HSCT)for severe aplastic anemia (SAA)by compared with the same period of unrelated donor transplantation (UD- HSCT). METHODS: Of a cohort of 50 SAA patients between September 2012 and July 2014, 26 patients underwent UD- HSCT and 24 patients Haplo- HSCT. RESULTS: OS rate was 91.3% with a median follow-up of 9 (2-26)months. According to transplant type, there was no significant difference between UD- and Haplo-HSCT (96.1%vs 86.0%,P=0.30). 3 of 50 (6%)patients had primary engraft failure. Haplo- HSCT developed higher significantly incidence of Ⅱ- Ⅳ aGVHD (37.5%vs 3.83%,P=0.003)and cGVHD (37.5%vs 15.3%,P=0.030)than UD-HSCT. Haplo-HSCT also had significantly higher incidences of CMV viremia (78.2%vs 46.1%,P=0.005)and EBV viremia (43.1%vs 16.0%,P=0.040), respectively than UD-HSCT. But the incidences of hemorrhagic cystitis were similar between two transplant types (39.1%vs 23.0%,P=0.120). CONCLUSION: This study showed favorable outcome of Haplo-HSCT for SAA, which was comparable with UD-HSCT. SN - 0253-2727 UR - https://www.unboundmedicine.com/medline/citation/26876251/[HLA__haploidentical_donor_hematopoietic_transplantation_for_severe_aplastic_anemia_achieved_comparable_outcomes_with_HLA__unrelated_donor_transplantation]_ L2 - http://journal.yiigle.com/LinkIn.do?linkin_type=pubmed&issn=0253-2727&year=2016&vol=37&issue=1&fpage=35 DB - PRIME DP - Unbound Medicine ER -